Uniqure company information, Employees & Contact Information

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares Yahoo Finance

uniQure N.V. Announces Pricing of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants Quiver Quantitative

$345 Million Raised: Gene Therapy Leader uniQure Completes Upsized Offering for AMT-130 Launch Plans Stock Titan

uniQure Announces $200 Million Proposed Public Offering Yahoo Finance

Gene Therapy Leader uniQure Schedules Q2 2025 Earnings: Key Details for Investors Stock Titan

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding Yahoo Finance

$200 Million Share Offering: Gene Therapy Leader uniQure Seeks Capital for Transformative Therapies Stock Titan

208-Fold Enzyme Increase: uniQure's One-Time Gene Therapy Could Replace Weekly Infusions for Fabry Disease Stock Titan

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease Yahoo Finance

$300 Million Capital Raise: Gene Therapy Leader uniQure Prices Upsized Public Offering with Warrants Stock Titan

uniQure to Announce Second Quarter 2025 Financial Results Yahoo Finance

$175M Non-Dilutive Funding: uniQure Secures Major Financing for Huntington's Gene Therapy Launch Stock Titan

uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease Yahoo Finance

FDA Green Lights Accelerated Approval Plan for First-Ever Huntington's Disease Gene Therapy Treatment Stock Titan

uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer Yahoo Finance

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress Yahoo Finance

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease Yahoo Finance

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease Yahoo Finance

uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE) Yahoo Finance

When Hope Turns Forward: AMT-130 Gene Therapy Milestone in Huntington’s Disease The Times of Israel

uniQure Reports Breakthrough Therapy Designation for AMT-130 and Financial Results for Q1 2025 Quiver Quantitative

uniQure N.V. Receives FDA Breakthrough Therapy Designation for AMT-130 in Huntington's Disease Treatment Quiver Quantitative

Huntington's Disease Breakthrough: uniQure's Gene Therapy Gets FDA Fast Track as Patient Data Shows Promise Stock Titan

Gene Therapy Leader uniQure Launches Quarterly Earnings Calls as AMT-130 Nears BLA Submission Stock Titan

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress Stock Titan

Revolutionary Gene Therapy for Huntington's Disease Earns FDA Breakthrough Status After Promising Trial Results Stock Titan

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease Yahoo Finance

A One‑Time Brain Gene Therapy Just Slowed Huntington’s by 75%—Is This the Turning Point Families Have Waited For? ts2.tech

uniQure N.V. Receives Positive Recommendation to Proceed with Second Dose Cohort in AMT-162 Clinical Trial for SOD1-ALS Quiver Quantitative

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease Yahoo Finance

uniQure N.V. to Report Second Quarter 2025 Financial Results and Host Conference Call on July 29, 2025 Nasdaq

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA PR Newswire

Experimental gene therapy for Huntington’s markedly slowed disease progression in key trial statnews.com

Additional Clarity: What We Know 4 Weeks After the uniQure News HDBuzz

uniQure Announces Update on U.S. Phase I/II Clinical Trial GlobeNewswire

uniQure and FDA Reach Accord on Approval Pathway for Huntington Disease Gene Therapy AMT-130 CGTLive®

uniQure hopes to launch 1st Huntington's gene therapy next year following phase 1/2 success Fierce Biotech

Novel Gene Therapy Significantly Slows Progression of Huntington Disease Pharmacy Times

uniQure N.V. Reports Progress with AMT-130 for Huntington’s Disease and Updates on Clinical Trials Across its Gene Therapy Pipeline Nasdaq

uniQure N.V. Announces Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants Nasdaq

Full Steam Ahead: uniQure’s On Track With Hope for Accelerated Approval of Huntington’s Disease Drug HDBuzz

Uniqure and its Huntington’s therapy win the week in biotech statnews.com

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen citybiz

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen citybiz

uniQure: Further Upside Likely As The Opportunity Becomes Better Understood (QURE) Seeking Alpha

CSL and uniQure Win 2023 Prix Galien USA Award PR Newswire

uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data Seeking Alpha

uniQure Announces 2021 Financial Results and Highlights Recent Company Progress Yahoo Finance

StockWatch: uniQure Shares Reach Five-Year High on “Game Changing” Huntington’s Data Genetic Engineering and Biotechnology News

uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million Yahoo Finance

uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress Yahoo Finance

UniQure ‘Exceeds Expectations’ in Much-Anticipated 3-Year Huntington’s Readout BioSpace

uniQure Announces Update on Low-Dose Cohort in Phase I/II GlobeNewswire

Here’s why biotech UniQure’s stock just tripled, and brought ClearPoint shares up with it MarketWatch

Gene therapy slows Huntington’s by 75 percent Longevity.Technology

uniQure Appoints Walid Abi-Saab, M.D., as Chief Medical Officer citybiz

UniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy Data (NASDAQ:QURE) Seeking Alpha

UniQure’s Regulatory Progress Sparks Optimism for ‘Desperate’ Huntington’s Space BioSpace

UniQure Wins First FDA RMAT in Huntington’s Disease After Strong Phase I/II Data BioSpace

Perspective on the Road toward Gene Therapy for Parkinson’s Disease Frontiers

UniQure restructuring to claim 300 jobs BioPharma Dive

uniQure Stock Jumps On Positive News, But Risks Remain - uniQure (NASDAQ:QURE) Benzinga

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street Benzinga

uniQure to Acquire Corlieve Therapeutics and Advance GlobeNewswire

uniQure Announces Appointment of Ricardo Dolmetsch, Ph.D., as President, Research & Development GlobeNewswire

UniQure sells gene therapy manufacturing site to Genezen, along with production of CSL's Hemgenix Fierce Pharma

Widespread and sustained target engagement in Huntington’s disease minipigs upon intrastriatal microRNA-based gene therapy Science | AAAS

Dutch gene therapy slows Huntington’s progression 75%, raises hopes for Alzheimer’s treatment - CHOSUNBIZ Chosun Biz

Research Program Johns Hopkins Medicine

uniQure announces FDA approval of first gene therapy for adults with hemophilia B BioSpace

BMS Terminates 2015 Gene Therapy Pact with uniQure BioSpace

uniQure N.V. (0EE0.L) stock price, news, quote and history Yahoo! Finance UK

uniQure NV (QURE) Stock Price, Trades & News GuruFocus

uniQure Appoints Matthew Kapusta as Chief Executive Officer GlobeNewswire

With its launch fizzling out, UniQure gives up on $1M+ gene therapy Glybera Fierce Pharma

QURE Stock Price and Chart — NASDAQ:QURE TradingView

Pulling the plug on the first gene therapy drug Medical Xpress